<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2 20190208//EN" "https://jats.nlm.nih.gov/publishing/1.2/JATS-journalpublishing1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Immunology</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Immunology</journal-title><trans-title-group xml:lang="ru"><trans-title>Russian Journal of Immunology</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1028-7221</issn><issn publication-format="electronic">2782-7291</issn><publisher><publisher-name xml:lang="en">Russian Society of Immunology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">65</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL ARTICLES</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">A STUDY ON THE ASSOCIATION OF <italic>IL‑1RAVNTR</italic> AND IL‑1α (С+889T) GENE POLYMORPHISMS WITH FEATURES OF ESSENTIAL HYPERTENSION</article-title><trans-title-group xml:lang="ru"><trans-title>ИЗУЧЕНИЕ СВЯЗИ ПОЛИМОРФИЗМА ГЕНА <italic>IL‑1RAVNTR</italic> И ВАРИАНТА IL‑1α (С+889T) С ОСОБЕННОСТЯМИ РАЗВИТИЯ ЭССЕНЦИАЛЬНОЙ АРТЕРИАЛЬНОЙ ГИПЕРТЕНЗИИ</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Radaeva</surname><given-names>O. A.</given-names></name><name xml:lang="ru"><surname>Радаева</surname><given-names>О. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD (Medicine), docent of chair of Immunology, Microbiology, Virology</p><p>26a, St. Ulyanova, Saransk</p></bio><bio xml:lang="ru"><p>к. м. н., доцент кафедры иммунологии, микробиологии, вирусологии медицинского института</p><p>430000, г. Саранск, ул. Ульянова, 26а</p></bio><email>vtlbwbyf_79@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Simbirtsev</surname><given-names>A. S.</given-names></name><name xml:lang="ru"><surname>Симбирцев</surname><given-names>А. С.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>PhD, MD (Medicine), Professor, Corresponding member of the Russian Academy of Sciences, deputy director of Institute of Highly Pure Biopreparations</p><p>7, St. Pudozhsky, St. Petersburg</p></bio><bio xml:lang="ru"><p>д. м. н., профессор, член-корр. РАН, заместитель директора</p><p>г. Санкт-Петербург</p></bio><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Mordovian State N. P. Ogariov University</institution></aff><aff><institution xml:lang="ru">ФГБОУ ВО “НИ МГУ им. Н.П. Огарева”</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">State Research Institute of Highly Pure Biopreparations</institution></aff><aff><institution xml:lang="ru">ФГУП “Гос.НИИ ОЧБ” ФМБА России</institution></aff></aff-alternatives><content-language>ru</content-language><pub-date date-type="pub" publication-format="electronic" iso-8601-date="2018-04-15"><day>15</day><month>04</month><year>2018</year></pub-date><pub-date date-type="collection"><year>2018</year></pub-date><volume>21</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>118</fpage><lpage>127</lpage><history><date date-type="received" iso-8601-date="2020-04-15"><day>15</day><month>04</month><year>2020</year></date><date date-type="accepted" iso-8601-date="2020-04-15"><day>15</day><month>04</month><year>2020</year></date></history><pub-history><event event-type="received"><event-desc>Received:<date date-type="received" iso-8601-date="2020-04-15"><day>15</day><month>04</month><year>2020</year></date></event-desc></event><event event-type="accepted"><event-desc>Accepted:<date date-type="accepted" iso-8601-date="2020-04-15"><day>15</day><month>04</month><year>2020</year></date></event-desc></event><event event-type="pub"><event-desc>Published:<pub-date date-type="pub" publication-format="electronic" iso-8601-date="2018-04-15"><day>15</day><month>04</month><year>2018</year></pub-date></event-desc></event></pub-history><permissions><copyright-statement xml:lang="en">Copyright ©; 2018, Radaeva O.A., Simbirtsev A.S.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2018, Радаева О.А., Симбирцев А.С.</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="en">Radaeva O.A., Simbirtsev A.S.</copyright-holder><copyright-holder xml:lang="ru">Радаева О.А., Симбирцев А.С.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://rusimmun.ru/jour/article/view/65">https://rusimmun.ru/jour/article/view/65</self-uri><abstract xml:lang="en"><p><italic>Objective:</italic> the analysis of the relationship between polymorphisms IL1-raVNTR, С+889T gene IL-1α and features of essential hypertension (the risk myocardial infarction and stroke among men and women).</p><p><italic>Methods:</italic> The 300 patients with II stage essential hypertension were followed for 8 years. Polymorphism of cytokine genes (IL-1ra (86 bp VNTR),–889C/T IL-1α) were examined by the method restrictor analysis of amplification products specific regions of the genome. Concentrations of IL-1ra, IL-1α in serum were measured by ELISA (test systems eBioscience (Bender MedSystems)).</p><p><italic>Results:</italic> Genotyping of interleukin 1 receptor antagonist genes (IL-1ra86bp VNTR) has shown positive associations between the intron 2 IL-1ra – 4R/4R, 5R/5R microsatellite polymorphism and the risk of arterial hypertension development. The 5R/5R, 2R/2R were associated significantly with risk of stroke and myocardial infarction in patients with essential hypertension. Patients with polymorphisms of IL-1ra 4R/4R and 5R/5R have a lower concentration of IL-1Pa and higher levels of IL-1α in serum than otherpatients. Variant TT polymorphism –889C/T IL-1α is correlated with an increase in the concentration of IL-1α in the serum, without changing the frequency of hypertension, but increases the risk of myocardial infarction and stroke in patients with hypertension (mostly women). Allele 4R/4R (IL1-raVNTR) is associated with hypertension and its combination with – TT variant with IL-1alpha (C + 889T) polymorphisms contribute to the development of myocardial infarction and stroke in women.</p></abstract><trans-abstract xml:lang="ru"><p><italic>Цель исследования</italic> – проанализировать связь частоты интронного полиморфизма IL1-raVNTR и варианта гена IL-1α (С+889T) с особенностями развития ЭАГ, формированием осложнений (ИМ, ОНМК) с учетом гендерной принадлежности.</p><p><italic>Материалы и методы.</italic> В течение 8 лет проводилось комплексное обследование 300 больных с ЭАГ II стадии. Полиморфизм генов цитокинов исследовали методом рестриктного анализа продуктов амплификации специфических участков генома. Концентрации IL-1ra, IL-1α определяли иммуноферментным методом (тест-системы eBioscience (BenderMedSystems)).</p><p><italic>Результаты.</italic> Развитие ЭАГ ассоциируется с генетическими вариантами IL-1ra – 4R/4R и 5R/5R, но при этом сочетание 4R/4R сопровождается меньшей частотой развития ИМ и ОНМК на фоне гипертензии, чем 5R/5R и 2R/2R. Пациенты с полиморфизмами IL-1ra 4R/4R и 5R/5R на фоне меньшей концентрации в сыворотке IL-1ra имеют достоверно более высокий уровень IL-1α. Вариант ТТ полиморфного участка –889C/T IL-1α соотносится с увеличением сывороточной концентрации цитокина, без достоверного первичного повышения риска развития гипертонии, но с увеличением частоты осложнений при наличии заболевания, чаще встречается у женщин с ЭАГ. У пациенток сочетание вариантов IL1-raVNTR/IL-1α(С+889T) – 4R4R/ТТ – приводит к достоверному повышению риска формирования гипертонии на фоне повышенного синтеза IL-1α с последующим развитием осложнений (ИМ, ОНМК) до 100% случаев.</p></trans-abstract><kwd-group xml:lang="en"><kwd>IL-1ra</kwd><kwd>IL-1α</kwd><kwd>gene polymorphism</kwd><kwd>essential hypertension</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>IL-1ra</kwd><kwd>IL-1α</kwd><kwd>полиморфизм генов</kwd><kwd>артериальная гипертензия</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>1. Rodriguez-Iturbe B., Pons H., Quiroz Y. The Immunological Basis of Hypertension. American Journal of Hypertension 2014, 27(11), 1327–1337.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>2. Vanhala M., Kautiainen H., Kumpusalo E. Proinflammation and hypertension: a population-based study. Mediators of Inflammation, vol. 2008, Article ID619704, 7 pages. doi:10.1155/2008/619704</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>3. Peddareddygari L.R., Sen S., PahwaA., Levenstien M.A., Grewal R.P. Analysis of the interleukin-1 receptor antagonist gene variable number tandem repeats in ischemic stroke. J. Stroke Cerebrovasc. Dis. 2014, 23(6), 1599–1603.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>4. Gromadzka G., Sarzynska-Dlugosz I., Czlonkowska A. IL1R Nintron 2 polymorphism caused by variable number tandem repeats is associated with 1-year outcome in patients with ischaemic stroke. J. Neurol. Neurosurg. Psychiatry. 2007, 78(2), 183–186.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>5. Симбирцев А.С. Интерлейкин-1. Физиология. Патология. Клиника. Спб.: Фолиант, 2011, 480. [Simbirtsev A.S. Interleukin-1. Physiology. Pathology. Clinic. “Izdatel’stvoFoliant”, St. Petersburg, 2011, 480].</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>6. Goto H., Ishihara Y., Kikuchi T., Izawa A., Ozeki N. Interleukin-1 Receptor Antagonist Has a Novel Function in the Regulation of Matrix Metalloproteinase-13 Expression. PLoS ONE2010, 10(10), e0140942. http://doi.org/10.1371/</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>7. Радаева О.А., Симбирцев А.С. Гендерные особенности системы интерлейкина-1 у женщин с эссенциальной артериальной гипертензией. Цитокины и воспаление 2014, Т. 13, № 3, 31–37. [Radaeva O.A., Simbirsev A.S. Gender-dependent changes in interleukin 1 system in women with essential arterial hypertension. Cytokines and Inflammation 2014, T. 13, № 3, 31–37].</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>8. Boodram Laura-Lee. Extraction of genomic DNA from whole blood / Protocol Online – Your Lab's Reference Book – online database of research protocols in a variety of life science fields. 1999–2006. http://www.proto-colorg/prot/Protocols/Extraction-of-genomic-DNA-from-whole-blood-3171.html.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>9. Goracy J., Goracy I., Safranow K., Taryma O. Lack of association of interleukin-1 gene cluster polymorphisms with angiographically documented coronary artery disease: demonstration of association with hypertension in the Polish population. Arch. Med. Res. 2011, 42(5), 426–432.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>10. Aren W.P., Malyak M., Guthridge C.J. Interleukin-1 receptor antagonist: Role in Biology. Annu. Rev. Immunol. 1998, 16, 2–55.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>11. Nicklin M.J., Hughes D.E., Barton J.L., Ure J.M., Duff G.W. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J. Exp. Med. 2000, 191(2), 303–312.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>12. Witkin S.S., Gerber S., William J. Ledger Influence of Interleukin-1 Receptor Antagonist Gene Polymorphism on Disease. Clin. Infect. Dis. 2002, 34 (2), 204–209</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>13. Herbert A., Cruickshank J.K., Laurent S., Boutouyrie P. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur. HeartJ. 2014, 35(44), 3122–3133.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>14. Xu S., Zhi H., Hou X., Cohen R.A., Jiang B. IκBβ attenuates angiotensin II–induced cardiovascular inflammation and fibrosis in mice. Hypertension 2011, 58, 310–316.</mixed-citation></ref></ref-list></back></article>
